Review





Similar Products

ndiff227  (TaKaRa)
96
TaKaRa ndiff227
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Ndiff227, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pmc13122662-428-8-9
Average 96 stars, based on 1 article reviews
ndiff227 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
ndiff227 medium  (TaKaRa)
96
TaKaRa ndiff227 medium
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Ndiff227 Medium, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pmc13122662-329-3-5
Average 96 stars, based on 1 article reviews
ndiff227 medium - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
pxgl  (TaKaRa)
96
TaKaRa pxgl
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Pxgl, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pmc13122662-329-0-5
Average 96 stars, based on 1 article reviews
pxgl - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
haploid esc culture haploid escs  (TaKaRa)
96
TaKaRa haploid esc culture haploid escs
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Haploid Esc Culture Haploid Escs, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pm41942435-390-0-10
Average 96 stars, based on 1 article reviews
haploid esc culture haploid escs - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
ndiff 227  (TaKaRa)
96
TaKaRa ndiff 227
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Ndiff 227, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pm41942435-390-8-10
Average 96 stars, based on 1 article reviews
ndiff 227 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
pbs  (TaKaRa)
96
TaKaRa pbs
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
Pbs, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pm41922518-539-5-11
Average 96 stars, based on 1 article reviews
pbs - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
n2b27  (TaKaRa)
96
TaKaRa n2b27
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
N2b27, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pm41922518-539-9-11
Average 96 stars, based on 1 article reviews
n2b27 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
2i media  (TaKaRa)
96
TaKaRa 2i media
Naive conversion with AICAR (A) Naive conversion protocol using AICAR. <t>PXGL;</t> PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) <t>in</t> <t>Ndiff227</t> medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .
2i Media, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y40002/NDiff+227/pmc12863184-157-19-25
Average 96 stars, based on 1 article reviews
2i media - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Journal: iScience

Article Title: AMPK-p38 axis converts human pluripotent stem cells to naive state

doi: 10.1016/j.isci.2026.115569

Figure Lengend Snippet: Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Article Snippet: For ectoderm differentiation, re-primed cells were cultured with Ndiff227 (Takara Bio) supplemented with hbFGF (Fujifilm,10 ng/ml), SB431542 (Tocris, 20 μM), and Noggin (R&D, 260 ng/ml) for 4 days, and then the medium was switched to Ndiff227 (Takara Bio) supplemented with hbFGF (Fujifilm,10 ng/ml) and SB431542 (Tocris, 20 μM).

Techniques: Flow Cytometry, Expressing, Quantitative RT-PCR, Immunostaining, Fluorescence, Microscopy

Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Journal: iScience

Article Title: AMPK-p38 axis converts human pluripotent stem cells to naive state

doi: 10.1016/j.isci.2026.115569

Figure Lengend Snippet: Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Article Snippet: PXGL is the Ndiff227 medium (Takara Bio) supplemented with PD0325901 (1 μM, Sigma), XAV939 (2 μM, Millipore), Go6983 (2 μM, Fujifilm), human LIF (10 ng/ml, Fujifilm), and penicillin/streptomycin (Meiji).

Techniques: Flow Cytometry, Expressing, Quantitative RT-PCR, Immunostaining, Fluorescence, Microscopy

Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Journal: iScience

Article Title: AMPK-p38 axis converts human pluripotent stem cells to naive state

doi: 10.1016/j.isci.2026.115569

Figure Lengend Snippet: Naive conversion with AICAR (A) Naive conversion protocol using AICAR. PXGL; PD0325901 (1 μM), XAV939 (2 μM), Go6983 (2 μM), and human LIF (10 ng/mL) in Ndiff227 medium. (B) Flow cytometry analysis of EOS-GFP, SUSD2, CD75, and CD57 expression (day 14). (C) Appearance of EOS-GFP-positive cell clusters induced by AICAR (day 14). (D) EOS-GFP-positive naive-like colony after expansion in PXGL (day 14 + 14p). (E) Flow cytometry analysis of EOS-GFP, SUSD2, and CD75 expression (day 14 + 21p). (F) RT-qPCR analysis of sorted SUSD2 + CD75 + cells and parental primed human ESCs (H9-EOS). AICAR, day 14 + 13p; VPA, day 9 + 4p. Error bars: SD of technical triplicates. (G) Immunostaining for OCT4, NANOG, KLF17, and TFE3 of primed and AICAR-induced cells. AICAR, day 14 + 14p. (H) AICAR-treated cells showed increased TMRE fluorescence, as detected by both flow cytometry (PE channel) and fluorescence microscopy. Scale bars: 100 μm in (C, D, and H) and 50 μm (G). AICAR, day 14 + 16p. See also and and .

Article Snippet: PXGL is the Ndiff227 medium (Takara Bio) supplemented with PD0325901 (1 μM, Sigma), XAV939 (2 μM, Millipore), Go6983 (2 μM, Fujifilm), human LIF (10 ng/ml, Fujifilm), and penicillin/streptomycin (Meiji).

Techniques: Flow Cytometry, Expressing, Quantitative RT-PCR, Immunostaining, Fluorescence, Microscopy